Literature DB >> 18308197

The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.

Mohamad Navab1, G M Anantharamaiah, Alan M Fogelman.   

Abstract

Apolipoprotein mimetic peptides have been shown to dramatically reduce atherosclerosis in animal models. Atherosclerosis is an example of an inflammatory disorder. Published studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis suggest that they may have efficacy in a wide range of inflammatory conditions.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18308197      PMCID： PMC4365994          DOI： 10.1016/j.tcm.2007.12.006

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN： 1050-1738            Impact factor:   6.677


  36 in total

1.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.

Authors:  G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

2.  When pouring water on the fire makes it burn brighter.

Authors:  Alan M Fogelman
Journal:  Cell Metab       Date:  2005-07       Impact factor: 27.287

3.  Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids.

Authors:  Peter S Gargalovic; Minori Imura; Bin Zhang; Nima M Gharavi; Michael J Clark; Joanne Pagnon; Wen-Pin Yang; Aiqing He; Amy Truong; Shilpa Patel; Stanley F Nelson; Steve Horvath; Judith A Berliner; Todd G Kirchgessner; Aldons J Lusis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-15       Impact factor: 11.205

4.  Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides.

Authors:  P G Yancey; J K Bielicki; W J Johnson; S Lund-Katz; M N Palgunachari; G M Anantharamaiah; J P Segrest; M C Phillips; G H Rothblat
Journal:  Biochemistry       Date:  1995-06-20       Impact factor: 3.162

5.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Authors:  Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Jacques Lespérance; Therese M Heinonen; Simon Kouz; Colin Berry; Russell Basser; Marc-André Lavoie; Marie-Claude Guertin; Josep Rodés-Cabau
Journal:  JAMA       Date:  2007-03-26       Impact factor: 56.272

6.  D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes.

Authors:  Brian J Van Lenten; Alan C Wagner; Mohamad Navab; G M Anantharamaiah; Eric Ka-Wai Hui; Debi P Nayak; Alan M Fogelman
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

7.  L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.

Authors:  Jingsong Ou; Zhijun Ou; Deron W Jones; Sandra Holzhauer; Ossama A Hatoum; Allan W Ackerman; Dorothee W Weihrauch; David D Gutterman; Karen Guice; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

8.  Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats.

Authors:  Stephen J Peterson; Daniel Husney; Adam L Kruger; Rafal Olszanecki; Francesca Ricci; Luigi F Rodella; Alessandra Stacchiotti; Rita Rezzani; John A McClung; Wilbert S Aronow; Susumu Ikehara; Nader G Abraham
Journal:  J Pharmacol Exp Ther       Date:  2007-05-08       Impact factor: 4.030

9.  Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts.

Authors:  George R Hsieh; Gabriel T Schnickel; Consuelo Garcia; Ali Shefizadeh; Michael C Fishbein; Abbas Ardehali
Journal:  Transplantation       Date:  2007-07-27       Impact factor: 4.939

10.  Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging.

Authors:  Ben J Wu; Krishna Kathir; Paul K Witting; Konstanze Beck; Katherine Choy; Cheng Li; Kevin D Croft; Trevor A Mori; David Tanous; Mark R Adams; Antony K Lau; Roland Stocker
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307
View more
  19 in total

Review 1.  The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges.

Authors:  David R Greaves; Siamon Gordon
Journal:  J Lipid Res       Date:  2008-12-11       Impact factor: 5.922

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Authors:  Laurent Yvan-Charvet; Jelena Kling; Tamara Pagler; Hongna Li; Brian Hubbard; Tim Fisher; Carl P Sparrow; Andrew K Taggart; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

4.  ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis.

Authors:  Laurent Yvan-Charvet; Tamara A Pagler; Tracie A Seimon; Edward Thorp; Carrie L Welch; Joseph L Witztum; Ira Tabas; Alan R Tall
Journal:  Circ Res       Date:  2010-04-29       Impact factor: 17.367

5.  Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.

Authors:  Nosratola D Vaziri; Hyun Ju Kim; Hamid Moradi; Farbod Farmand; Kaveh Navab; Mohamad Navab; Susan Hama; Alan M Fogelman; Yasmir Quiroz; Bernardo Rodriguez-Iturbe
Journal:  Nephrol Dial Transplant       Date:  2010-05-20       Impact factor: 5.992

Review 6.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 7.  HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.

Authors:  G S Getz; G D Wool; C A Reardon
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 8.  Biological properties of apolipoprotein a-I mimetic peptides.

Authors:  Godfrey S Getz; Geoffrey D Wool; Catherine A Reardon
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

9.  Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.

Authors:  David Meriwether; Satoshi Imaizumi; Victor Grijalva; Greg Hough; Ladan Vakili; G M Anantharamaiah; Robin Farias-Eisner; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Ishaiahu Shechter
Journal:  J Lipid Res       Date:  2011-07-29       Impact factor: 5.922

10.  The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.

Authors:  C Roger White; Geeta Datta; Landon Wilson; Mayakonda N Palgunachari; G M Anantharamaiah
Journal:  Chem Phys Lipids       Date:  2019-01-29       Impact factor: 3.329
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.